Background
There is no proven therapy for HFpEF. In the absence of data, medicines with established benefit in HFrEF such as vasodilators are frequently prescribed for HFpEF.
Methods
We compared baseline hemodynamics and acute responses to vasodilation with intravenous sodium nitroprusside in patients with HFrEF (n ϭ 174) and HFpEF (n ϭ 83), determined invasively by cardiac catheterization.
Results
Baseline blood pressure, stroke volume, and cardiac output were greater in HFpEF than HFrEF, while pulmonary artery mean and pulmonary wedge pressures were similar. Left ventricular filling pressures were reduced to a similar extent in each group with nitroprusside, but the drop in systemic arterial pressure was 2.6-fold greater in HFpEF (p Ͻ 0.0001), and improvements in stroke volume and cardiac output were each ϳ60% lower in HFpEF compared to HFrEF (p Ͻ 0.0001). Despite similarly elevated filling pressures, HFpEF patients were fourfold more likely than HFrEF to experience a reduction in stroke volume with nitroprusside (p Ͻ 0.0001), suggesting greater vulnerability to preload reduction. Pulmonary artery systolic pressure dropped more in HFpEF than in HFrEF despite similar reduction in pulmonary mean pressure and resistance, suggesting higher right ventricular systolic elastance in HFpEF.
Conclusions
As compared to patients with HFrEF, patients with HFpEF experience greater blood pressure reduction, less enhancement in cardiac output, and greater likelihood of stroke volume drop with vasodilators. These findings emphasize fundamental differences in the 2 HF phenotypes and suggest that more pathophysiologically targeted therapies are needed for HFpEF. Approximately one-half of patients with heart failure (HF) have preserved ejection fraction (HFpEF) and the remainder have heart failure with reduced ejection fraction (HFrEF) (1) . Clinical presentation is similar in both forms of HF, and because abnormalities in ventricular and vascular function are common to each, it has been proposed that HFpEF and HFrEF are part of the same "HF continuum" (2) . However, therapies with unequivocal benefit in HFrEF have failed to show efficacy in HFpEF (3) (4) (5) , suggesting important pathophysiologic differences. In the absence of proven treatments for HFpEF, it is important to understand potential differences in response to empiric HF therapies, and appreciation of unique pathophysiology in the 2 types of HF may better inform selection of interventions to be tested in future trials.
Vasodilators are a cornerstone in the management of both decompensated and chronic HFrEF (3) (4) (5) (6) (7) . Favorable acute hemodynamic effects of vasodilation in HFrEF are due in large part to enhanced afterload sensitivity of the dilated, failing ventricle (7) (8) (9) . Although systolic function is not completely normal in HFpEF, both systolic and diastolic ventricular vascular stiffness are typically elevated (10, 11) , Theoretical and clinical data from small studies suggest that this combined ventricular-arterial stiffening may promote exaggerated blood pressure response to changes in ventricular loading in HFpEF, including hypertensive crisis with vasoconstriction, or hypotension with overly aggressive vasodilation (10, 12) .
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We sought to compare the acute hemodynamic effects of vasodilation with nitroprusside in patients with HFpEF and HFrEF. We hypothesized that hemodynamic changes with vasodilation are fundamentally different in the 2 HF populations-with greater systemic arterial pressure drop and less augmentation of stroke volume in HFpEF as compared to HFrEF.
Methods

Study population.
We examined consecutive patients with HF referred to the Mayo Clinic cardiac catheterization laboratory between October 2002 and July 2009 for right heart catheterization (with or without left heart catheterization) who underwent acute vasodilator challenge with intravenous sodium nitroprusside. Nitroprusside is routinely administered in our laboratory when pulmonary wedge pressure is elevated to assess reversibility. Patients with primary left-sided valvular heart disease, cardiac transplantation, on inotrope or pressor therapy, with complex congenital disease or shock were excluded. The study was approved by the Mayo Clinic institutional review board. Catheterization protocol. Patients were studied receiving chronic medications in the fasted state after minimal sedation in the supine position. Standard right heart catheterization was performed through the internal jugular or femoral vein. Left heart catheterization was performed by the retrograde transaortic approach from the radial or femoral artery, as described previously (13) , in a subset of patients (n ϭ 89). All measurements were performed at end-expiration off line by 1 investigator (S.S.) from electronically stored continuous recordings of pressure tracings. Systemic arterial blood pressure (BP) was measured invasively (n ϭ 217) or by cuff sphygmomanometry (n ϭ 40). Cardiac output was determined by the Fick method or by thermodilution. Stroke volume (SV) was determined by cardiac output divided by heart rate. Nitroprusside infusion. After baseline hemodynamic data were acquired, sodium nitroprusside was administered at incremental doses starting at 0.25 to 0.5 g/kg/min, titrated to: 1) normalization in pulmonary wedge pressure; 2) reduction in systolic BP to Ͻ90 mm Hg; or 3) patient intolerance (e.g., lightheadedness). Hemodynamic measurements were then repeated. Case definitions. Clinical data were obtained from detailed chart review. Echocardiographic data was abstracted from clinically obtained studies performed before catheterization. HFpEF was defined by cardiologist adjudicated HF diagnosis (Framingham criteria), EF Ͼ50%, the absence of significant valvular disease (more than moderate left-sided regurgitation or any stenosis), and after exclusion of patients with constrictive pericarditis, and infiltrative, restrictive, or hypertrophic cardiomyopathies. HFrEF was defined employing the same criteria, with EF Ͻ50%. Patients with HFrEF and functional mitral regurgitation were not excluded, provided that primary mitral valve pathology was absent. Hemodynamic definitions. LV end-systolic and enddiastolic volumes were determined from the Teicholz method based upon echocardiography. Left ventricular preload was defined by end-diastolic volume (12) . LV endsystolic volume changes during nitroprusside infusion were estimated by the difference in echocardiographic end-diastolic volume and directly measured SV. LV endsystolic pressure was taken as 0.9*systolic BP. The LV endsystolic elastance (Ees) was estimated by the ratio of end-systolic pressure to end-systolic volume. Systemic arterial afterload was assessed by effective arterial elastance (Ea), defined as the ratio of end-systolic pressure to SV (12) . Ventricular-arterial coupling was assessed by the ratio of Ea/Ees (12) . Pulsatile load, referring to the nonresistive, oscillatory components of arterial afterload, was assessed by systemic arterial pulse pressure and compliance (SV divided by pulse pressure) (14) . Pulmonary vascular resistance was determined using standard formula (13) . Statistical analysis. Data are reported as mean Ϯ SD or median (25th, 75th interquartile range). Between-group differences were compared by t test, Wilcoxon rank-sum test, or chi-square. Bivariate regression (Pearson coefficient) was used to examine correlations between continuous measures. Multivariable linear regression analysis was used to adjust for relevant baseline group differences, in which the dependent variable was the normally distributed continuous or categorical outcome variable of interest, and factors entered into the model included age, sex, body mass, group (dummy variable), and relevant interaction terms. For non-normally distributed variables entered into regression models, the assumption of normally distributed residuals was verified by quantile plots, and no major violations were observed. (Table 1) . Patients with HFrEF were more likely to be treated with beta-blockers, digoxin, and inhibitors of the angiotensin-aldosterone axis, and less likely to be treated with calcium-channel blockers compared with HFpEF patients. Most patients were receiving diuretics. Natriuretic peptide and serum hemoglobin levels were higher in HFrEF patients. Cardiomegaly on chest film was more common in HFrEF patients.
Results
Subject
Echocardiography was performed a median of 6 days (interquartile range: 2 to 28 days) before catheterization, with no difference between groups in the interval (p ϭ 0.60). LV chamber dimension, mass, volumes, and left atrial size were greater in HFrEF, whereas wall thickness and the ratio of wall thickness to chamber volume were higher in HFpEF (Table 1) . Patients with HFrEF more commonly displayed qualitative right ventricular systolic dysfunction and had more severe LV diastolic dysfunction based upon Doppler echocardiography, compared with HFpEF. Baseline hemodynamics. At rest, right atrial, mean pulmonary artery, and pulmonary wedge pressures were similar in HFpEF and HFrEF, although LV end-diastolic pressures were somewhat higher in HFrEF (Table 2 ). Patients with HFpEF had higher BP, pulmonary artery systolic pressure, cardiac output, and SV compared with HFrEF, while heart rate and pulmonary vascular resistance were similar in both groups. Pulmonary artery saturations were lower in HFrEF compared with HFpEF, yet 75% of HFpEF patients displayed saturations below the normal range (Ͻ68%), consistent with inadequate perfusion relative to metabolic needs. The pulsatile contribution to systemic arterial pressure was greater in HFpEF, evidenced by higher pulse pressure, lower arterial compliance, and greater systolic BP for any arterial elastance (Ea) (Fig. 1) . Ventricular-arterial coupling Values are mean Ϯ SD, %, or median (25th to 75th interquartile range). *Refers to qualitative impression based upon echocardiography, as abstracted from the clinical records. ACEI ϭ angiotensin-converting enzyme inhibitor; ARB ϭ angiotensin-receptor blocker; BNP ϭ brain natriuretic peptide; COPD ϭ chronic obstructive pulmonary disease; E/A ϭ transmitral early to late filling velocity ratio; E/e' ϭ early diastolic transmitral flow to tissue velocity ratio; GFR ϭ glomerular filtration rate; HFpEF ϭ heart failure with preserved ejection fraction; HFrEF ϭ heart failure with reduced ejection fraction; LV ϭ left ventricular; NT-proBNP ϭ N-terminal pro-brain natriuretic peptide; RV ϭ right ventricular.
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was more deranged in HFrEF: LV Ees was nearly an order of magnitude lower compared with HFpEF (Table 2) , whereas baseline Ea was somewhat higher in HFpEF. The coupling ratio (Ea/Ees) was fivefold higher in HFrEF compared with HFpEF, consistent with afterload mismatch. All group differences persisted after adjusting for age, sex, and body mass index. Hemodynamic responses with nitroprusside. There was no difference in nitroprusside dose administered between the groups (Table 3) . Cardiac output was remeasured during Baseline Hemodynamics Values are mean Ϯ SD or median (25th to 75th interquartile range). BP ϭ blood pressure; Ea ϭ effective arterial elastance; Ees ϭ left ventricular end-systolic elastance; PA ϭ pulmonary artery; PCWP ϭ pulmonary capillary wedge pressure; PVR ϭ pulmonary vascular resistance; SV ϭ stroke volume; other abbreviations as in Table 1 .
Figure 1 Pulsatile Arterial Loading in HFpEF and HFrEF
Pulsatile afterload was greater in heart failure with preserved ejection fraction (HFpEF) (black) compared with heart failure with reduced ejection fraction (HFrEF) (red), with higher pulse pressure, lower arterial compliance, and higher systolic arterial pressure for a given arterial elastance. The p values are shown for ‫ء‬bivariate, †group, and ‡interaction term comparisons. BP ϭ blood pressure.
445
Vasodilation in HFpEF and HFrEF nitroprusside in 157 HFrEF patients and 51 HFpEF patients, and all subjects had paired measures of pressure data. There were no differences in baseline characteristics between patients who did and did not have cardiac output remeasured during nitroprusside (Online Appendix). Despite similar reductions in systemic afterload (Ea) with nitroprusside in both groups, patients with HFpEF experienced ϳ2.5-and ϳ1.7-fold greater drops in systolic and mean arterial BP compared with HFrEF (Fig. 2, Table 3 ).
Conversely, patients with HFrEF displayed twofold to 3-fold greater increases in SV and cardiac output compared with HFpEF. The proportional increase in SV (relative to baseline) with nitroprusside was fourfold greater in HFrEF than HFpEF (ϩ49 Ϯ 50% vs. ϩ13 Ϯ 31%, p Ͻ 0.0001). Changes in heart rate and LV filling pressures with nitroprusside were similar in HFrEF and HFpEF (Fig. 2 , Table 3 ). Each of these differences persisted after adjusting for age, sex, body mass index, and nitroprusside dose. 
Hemodynamic Changes With Nitroprusside
Figure 2 Peripheral and Central Hemodynamic Changes With Nitroprusside
Nitroprusside caused greater blood pressure (BP) reduction in heart failure with preserved ejection fraction (HFpEF) (black) compared with heart failure with reduced ejection fraction (HFrEF) (red), whereas augmentation in stroke volume (SV) and cardiac output were greater in HFrEF compared with HFpEF. PCWP ϭ pulmonary capillary wedge pressure; SBP ϭ systolic blood pressure.
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The HFrEF patients with significant (grade 3 to 4) mitral regurgitation tended to show greater hemodynamic improvements compared to HFrEF patients without mitral regurgitation, but after restricting the analysis to HFrEF without significant mitral regurgitation, each of the HFpEF-HFrEF group comparisons remained highly significant (Online Appendix). Group differences in stroke volume, cardiac output, and blood pressure persisted after recategorizing HFpEF as patients with EF Ͼ45% and EF Ͼ40%. Figure 3A shows the distributions of SV change with nitroprusside in HFrEF and HFpEF. Despite the predominant arterial vasodilator properties of nitroprusside (6) and the presence of elevated LV filling pressures, SV actually decreased in 35% of HFpEF patients with nitroprusside, compared with only 9% of HFrEF patients (p Ͻ 0.0001). Subgroup analysis revealed that baseline pulmonary capillary wedge pressure was lower and the increase in heart rate greater with nitroprusside among patients with a drop in SV compared to patients with enhanced SV, but LV filling pressures were elevated in both groups (Online Appendix). Importantly, observed disparities in BP, SV, and cardiac output response to nitroprusside in HFpEF and HFrEF persisted after excluding patients with SV reduction or with baseline pulmonary wedge pressures below 20 or 25 mm Hg (Online Appendix). Determinants of the nitroprusside response. The reduction in BP with nitroprusside correlated with the decrease in arterial afterload (Ea) in all patients (p Ͻ 0.0001), but for any drop in Ea, the reduction in systolic BP was steeper in HFpEF compared with HFrEF (group p Ͻ 0.0001; interaction term p ϭ 0.003) (Fig. 3B) . These differences persisted after adjusting for age, sex, and body mass index. Changes in pulmonary wedge pressure with nitroprusside were not related to changes in BP, SV, heart rate, cardiac output, or Ea. Enhancement in SV as a function of LV filling pressure was greater in HFrEF than HFpEF (Fig. 3C) .
Changes in LV end-systolic pressure and estimated end-systolic volume with nitroprusside are displayed graphically in Figure 4 , plotting median baseline Ees estimates (solid lines), end-diastolic volumes from echocardiography, and observed reductions in Ea (dashed lines). Assuming that Ees and end-diastolic volume did not change on average with nitroprusside, observed changes in end-systolic pressure-volume coordinates (diamonds) fall very close to (Fig. 4) . Right-sided ventricular-arterial coupling. Despite similar mean pressures, pulmonary artery systolic pressure was higher in HFpEF than in HFrEF (Table 2) , even after adjusting for pulmonary wedge pressure, pulmonary vascular resistance, and SV. With nitroprusside, pulmonary artery systolic pressure decreased more in HFpEF than in HFrEF despite similar changes in pulmonary wedge pressure and pulmonary arteriolar resistance (Table 3) . After adjusting for changes in pulmonary wedge pressure and pulmonary vascular resistance, the drop in pulmonary arterial systolic pressure was greater in HFpEF than in HFrEF (Fig. 3D) , suggesting higher right ventricular Ees in HFpEF and greater right ventricular afterload mismatch in HFrEF.
Discussion
We compared hemodynamics at rest and during nitroprusside infusion in a large cohort of well-characterized patients with HF and preserved or reduced ejection fraction. . As in the current study, LV filling pressures at rest were similarly elevated in HFpEF and HFrEF, leading the authors to suggest that hemodynamics alone do not distinguish these HF phenotypes. Although the current data confirm similarities in filling pressures at baseline, they highlight important, fundamental differences in arterial pressure and flow responses with vasodilation in HFpEF and HFrEF in both the left-and right-sided circulations. These findings may have important implications for the care of patients with HFpEF. Ventricular-arterial interaction in HF. Changes in BP and SV with alteration in ventricular loading conditions are predictable based upon concepts of ventricular-arterial coupling (8, 9, 12, 16) . BP decreases while the SV increases with vasodilation, and the extent of change in each is dictated by slope and intercept of the end-systolic pressure volume relationship, termed end-systolic elastance (Ees) (Fig. 4) . While elevated arterial afterload (Ea) is common to both forms of HF, the 2 entities differ dramatically in the "active" stiffness (contractility) developed by the heart at end systole, or Ees (8, 17) . In HFpEF, Ees is elevated (10), despite mild abnormalities in myocardial and chamber contractility (11) , likely because passive components of stiffness are elevated (15) . In an elegant study, Kawaguchi et al. (10) demonstrated that elevated Ees in HFpEF leads to an exaggerated hypertensive response to isometric handgrip, providing mechanistic insight into to the hypertensive pulmonary edema commonly observed in these patients (18) . We show for the first time in a large series of HFpEF patients the converse is also true: with acute decreases in afterload, there are also more dramatic drops in BP. The average changes in pressure and volume were strikingly similar to those predicted based upon median estimated end-systolic pressurevolume relationships in HFpEF patients (Fig. 4) .
In contrast, the shallow end-systolic pressure volume relationship in HFrEF (low Ees) (Fig. 4) predicts the opposite: lesser drop in BP and higher gain in SV with Ea reduction. This phenomenon allows HFrEF patients to tolerate very high doses of vasodilators without hemodynamic embarrassment, as previously described (6 -8) . In healthy humans, Ees and Ea are closely matched to optimize stroke work and efficiency, with Ea/Ees ratios of 0.5 to Figure 4 Observed and Predicted End-Systolic Pressure-Volume Changes With Nitroprusside
Observed changes in estimated end-systolic pressure-volume coordinates (diamonds) in heart failure with preserved ejection fraction (HFpEF) (black) compared with heart failure with reduced ejection fraction (HFrEF) (red) with reduction in arterial elastance (Ea) (dashed lines) were very similar to those predicted based on resting left ventricular end-systolic elastance (Ees) (straight lines) and the observed changes in Ea. See text for details. 
